Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Completed 2Withdrawn 1Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Head and Neck Neoplasms 1Depression 1

Interventions

pembrolizumab 61Radiotherapy 55Gemcitabine 51Paclitaxel 49Cyclophosphamide 48Cisplatin 48Carboplatin 45Dexamethasone 37Bevacizumab 37Nivolumab 35Fluorouracil 34Docetaxel 34Oxaliplatin 33durvalumab 32Rituximab 28Magnetic Resonance Spectroscopy 28Leucovorin 28Drug Therapy 25Pemetrexed 24Doxorubicin 24Capecitabine 24atezolizumab 22Radiation 20Cytarabine 20Radiosurgery 19Prednisone 19Etoposide 19Irinotecan 17Bortezomib 17Cetuximab 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Withdrawn × Venlafaxine Hydrochloride × Clear all
NCT05724849 2024-01-18

Venlafaxine for the Prevention of Depression in Patients With Head and Neck Cancer

Vanderbilt University Medical Center

Phase 2 Withdrawn
Head & Neck

Depression, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡